A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

This is a multicenter, randomized, double-blinded, positive controlled study to evaluate the lot-to-lot consistency, immunogenicity and safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in adults aged 18 to 55 years. Subjects will be randomized to receive investigational Lot 1, Lot 2, Lot 3 vaccine or control vaccine in a 1:1:1:1 ratio, with the subjects in experimental group randomly and equally assigned to three different batches of MCV4 for single-dose vaccination.

NCT Number	NCT06131554
Lead Sponsor	CanSino Biologics Inc.
Conditions	Meningococcal Meningitis
Enrollment	1,480 participants
Start Date	2024-03-20
Primary Completion	2024-07-12 (estimated)
Study Completion	2025-06-04 (estimated)
Updated on ClinicalTrials.gov	2026-08-06